Efficacy and Safety of Eplontersen in Patients with Transthyretin Amyloid Cardiomyopathy
Mathew Maurer | Columbia University Irving Medical Center, New York, USA

RESULTS: Among patients with ATTR-CM, eplontersen did not reduce the risk of a composite of death from cardiovascular causes and recurrent cardiovascular clinical events compared with placebo through 140 weeks.

• NEJM: Eplontersen for Transthyretin Amyloid Cardiomyopathy
• NCT04136171

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Ahmad Masri | Oregon Health & Science University Medical Group, Portland, OR

RESULTS: In patients with symptomatic nHCM, treatment with aficamten was associated with significantly greater improvements in exercise capacity and patient-reported health status compared with placebo at 36 weeks.

• NEJM: Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
• Circulation: Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM
• Circulation Editorial: Structure-Function Relationship as the Foundation for Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy
• Circulation Editorial: Defining Meaningful Treatment Responses in Hypertrophic Cardiomyopathy: Seeking a Trifecta Across Phenotypes
• NCT06081894

Statins for Reducing Events in the Elderly
Sophia Zoungas | The George Institute for Global Health, Sydney, Australia

RESULTS: Treatment with atorvastatin resulted in a lower risk of major cardiovascular events, but did not prolong disability-free survival n community-dwelling adults at least 70 years of age with no history of cardiovascular disease, diabetes, or dementia.

• NEJM: Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
• NCT02099123

Edoxaban in Intracranial Hemorrhage Survivors with Atrial Fibrillation
Ashkan Shoamanesh | McMaster University, Hamilton, Canada

RESULTS: In patients with high-risk atrial fibrillation and prior intracranial hemorrhage, edoxaban did not reduce the risk of stroke or systemic embolism compared with non-anticoagulant medical therapy and was associated with a significantly increased risk of major bleeding.

• NCT03950076
• ENRICH-AF site

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
Philippe Gabriel Steg | Hospital Bichat-Claude Bernard, Paris, France

RESULTS: Compared with placebo, milvexian did not decrease the risk of cardiovascular death, myocardial infarction, or ischemic stroke and did not increase the risk of intracranial or fatal bleeding among patients with a recent acute coronary syndrome event.

• NEJM: Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
• NCT05754957

Tricuspid Intervention in Heart Failure
Joerg Hausleiter | Ludwig Maximilians University, Munich, Germany

RESULTS: In patients with symptomatic severe tricuspid regurgitation, transcatheter tricuspid valve repair plus medical therapy was superior to medical therapy alone with respect to clinical outcomes and quality of life.

• NEJM: Tricuspid-Valve Intervention in Heart Failure
• NCT04634266

Pulmonary Vein Isolation versus SHAM-Pulmonary Vein Isolation for Symptomatic Relief in Patients with Atrial Fibrillation
Rolf Wachter | University Hospital Leipzig, Leipzig, Germany

RESULTS: (released after presentation)

• The Lancet: Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial
• NCT05119231

Long-Term Blood Pressure Control and Dementia Risk
Shanshan Zhong | The First Affiliated Hospital of China Medical University, Shenyang, China

RESULTS: Intensive BP management led by NPCHPs was associated with lower 7-year risks of dementia and cognitive impairment not dementia (CIND) when compared with usual care, with benefits persisting after the active intervention ended.

• Circulation: Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial
• NCT03527719